As medical device and diagnostic manufacturers continue to develop life-enhancing products globally, product labels and instructions-for-use (IFUs) hold an increasingly important position - providing critical information to healthcare professionals, focused on the safe handling and use of devices.
Labeling executives strive to continuously optimize operations, ensuring a streamlined approach to label data collection and regulatory reviews, and face numerous challenges in achieving each step in line with regulatory requirements.
Subject matter experts from Acolad recently attended the Medical Device and Diagnostic Labeling Conference in Chicago, IL. During this conference, we were able to meet with medical device and labeling industry experts from all over the country, all of whom were interested in risk-based approaches to label development.
Conferences such as this one are a good opportunity to learn about trends and upcoming concerns in various industries, and this conference was no exception.
“There’s a really good range of people that we want to be talking to” at this conference, says Collette Bowers Vahed of Acolad. “This show is a very good filtered section of the population, and many of the people that we talk to are actually directly involved in translation.”
“It’s an intimate show,” says Bowers Vahed. This helps Acolad speak with various delegates individually about the challenges in each company’s labeling landscape and their stance on risk-based approaches to label development.
Acolad Life Sciences works extensively with both medical device and drug manufacturers on a global basis to address the compliance challenges related to risk-based approaches to label development.
Learn more about Acolad Life Sciences offerings for translations and packaging and labeling.
Updated